Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Last Close
Oct 04 11:25AM ET
44.97
Dollar change
+2.22
Percentage change
5.20
%
IndexRUT P/E- EPS (ttm)-23.00 Insider Own64.20% Shs Outstand12.06M Perf Week-2.23%
Market Cap542.40M Forward P/E- EPS next Y-5.28 Insider Trans-0.01% Shs Float4.32M Perf Month-1.82%
Income-65.02M PEG- EPS next Q-1.38 Inst Own16.61% Short Float11.07% Perf Quarter136.71%
Sales0.00M P/S- EPS this Y31.07% Inst Trans-18.43% Short Ratio4.33 Perf Half Y122.43%
Book/sh2.79 P/B16.10 EPS next Y-3.33% ROA-44.30% Short Interest0.48M Perf Year127.15%
Cash/sh8.93 P/C5.04 EPS next 5Y-9.40% ROE-85.06% 52W Range8.24 - 53.79 Perf YTD310.95%
Dividend Est.- P/FCF- EPS past 5Y-0.07% ROI-125.01% 52W High-16.39% Beta-0.30
Dividend TTM- Quick Ratio6.49 Sales past 5Y199.24% Gross Margin-132.49% 52W Low445.55% ATR (14)3.52
Dividend Ex-Date- Current Ratio6.49 EPS Y/Y TTM62.06% Oper. Margin0.00% RSI (14)53.55 Volatility7.02% 9.70%
Employees7 Debt/Eq0.59 Sales Y/Y TTM-100.00% Profit Margin- Recom1.00 Target Price77.80
Option/ShortYes / Yes LT Debt/Eq0.55 EPS Q/Q87.00% Payout- Rel Volume0.39 Prev Close42.75
Sales Surprise- EPS Surprise-42.47% Sales Q/Q-100.00% EarningsAug 08 BMO Avg Volume110.40K Price44.97
SMA20-0.89% SMA509.24% SMA20082.93% Trades Volume14,169 Change5.20%
Date Action Analyst Rating Change Price Target Change
Sep-11-24Initiated Wells Fargo Overweight $95
Jun-17-24Initiated Guggenheim Buy $100
May-21-24Initiated Leerink Partners Outperform $54
Apr-11-24Initiated Oppenheimer Outperform $50
Apr-02-24Initiated Piper Sandler Overweight $45
Jul-28-23Downgrade Robert W. Baird Outperform → Neutral $9 → $1.50
Feb-22-22Reiterated BTIG Research Neutral $35 → $29
Feb-22-22Downgrade RBC Capital Mkts Outperform → Sector Perform
Feb-22-22Downgrade Oppenheimer Outperform → Perform
Mar-02-21Initiated Stifel Hold $14
Aug-29-24 06:59AM
Jul-09-24 06:59AM
Jul-01-24 06:59AM
May-09-24 01:56PM
06:59AM
07:00AM Loading…
Apr-03-24 07:00AM
Mar-18-24 04:30PM
Mar-15-24 09:52PM
Mar-01-24 10:48AM
Jan-27-24 12:10PM
Jan-03-24 04:08PM
Nov-17-23 06:40AM
Nov-16-23 12:18PM
07:05AM
Nov-14-23 05:02PM
04:33PM Loading…
04:33PM
Aug-14-23 04:20PM
04:05PM
Jul-27-23 04:05PM
04:01PM
Jul-06-23 11:17AM
May-16-23 08:00AM
May-11-23 05:35PM
04:25PM
04:05PM
May-03-23 07:30AM
Mar-27-23 05:52AM
Mar-15-23 04:01PM
Mar-09-23 06:45PM
04:05PM
08:00AM Loading…
08:00AM
Mar-02-23 07:30AM
Feb-24-23 05:31AM
Feb-22-23 04:01PM
Jan-05-23 09:25AM
Jan-04-23 04:01PM
Nov-12-22 08:08AM
Nov-10-22 05:45PM
04:07PM
Oct-27-22 09:00AM
Oct-06-22 08:30AM
Sep-27-22 08:15AM
Sep-08-22 11:05AM
Sep-06-22 04:01PM
Aug-17-22 01:05PM
Aug-16-22 11:52AM
Aug-15-22 06:15PM
04:10PM
Aug-12-22 07:46AM
Aug-11-22 04:05PM
Jul-25-22 09:12AM
Jul-05-22 08:30AM
Jun-29-22 08:00AM
Jun-13-22 08:00AM
Jun-10-22 08:30AM
May-18-22 06:00AM
May-16-22 06:05PM
04:15PM
May-13-22 08:45AM
May-02-22 04:56PM
Apr-21-22 08:30AM
Mar-23-22 05:45PM
04:10PM
Mar-10-22 04:01PM
Mar-08-22 10:00AM
Mar-07-22 09:38AM
Mar-03-22 03:00PM
07:30AM
Feb-24-22 08:45AM
05:39AM
Feb-23-22 10:00AM
Feb-22-22 07:34AM
Feb-21-22 09:40AM
02:53AM
Feb-18-22 04:05PM
Feb-10-22 11:40AM
07:18AM
Feb-02-22 09:40AM
Jan-28-22 10:46AM
02:30AM
Jan-21-22 09:38AM
Dec-12-21 08:19AM
Dec-10-21 06:38PM
Nov-15-21 07:10AM
Nov-03-21 08:29AM
Nov-01-21 03:01PM
Oct-21-21 07:00AM
Oct-20-21 08:30AM
Oct-18-21 08:30AM
Oct-13-21 08:21AM
Oct-12-21 04:05PM
Oct-11-21 08:39AM
Aug-14-21 03:27AM
Aug-12-21 07:05PM
04:05PM
Aug-05-21 08:30AM
Aug-04-21 08:30AM
Aug-02-21 03:01PM
Jun-19-21 05:23AM
May-13-21 07:00AM
Q32 Bio, Inc. operates as a clinical stage biotechnology company developing biologic therapeutics targeting potent regulators of the innate and adaptive immune systems to re-balance immunity in autoimmune and inflammatory diseases. It focuses on the IL-7 / TSLP receptor pathways and complement system, addressing immune dysregulation to help patients take back control of their lives. The company was founded by David Grayzel and Shelia Violette in 2017 and is headquartered in Waltham, MA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
TZIANABOS ARTHURDirectorMar 25 '24Sale24.202656,4137,983Aug 14 04:05 PM
Alloway PaulSee RemarksMar 25 '24Sale24.212686,4882,596Apr 23 05:03 PM
Michaud Charles JrSee RemarksMar 25 '24Sale24.20751,815927Apr 23 05:00 PM
TZIANABOS ARTHURDirectorJan 09 '24Sale0.5713,0377,445128,778Feb 15 04:33 PM
Alloway PaulSee RemarksJan 03 '24Sale0.577,2804,12028,036Jan 05 05:54 PM
Michaud Charles JrSee RemarksJan 03 '24Sale0.571,70897511,598Jan 05 05:49 PM